Black Diamond Therapeutics Inc. Company Profile
NASDAQ: BDTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Black Diamond Therapeutics at a glance
Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Black Diamond Therapeutics is led by Dr. Mark A. Velleca M.D., Ph.D. and employs about 21 people. The company's shares have traded publicly since 2020.
At a market capitalization of $75.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001701541, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Black Diamond Therapeutics do?
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Black Diamond Therapeutics Inc.
- Ticker
- NASDAQ: BDTX
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Mark A. Velleca M.D., Ph.D.
- Employees
- 21
- Headquarters
- 245 First Street, Cambridge, MA, United States
- Phone
- 617 252 0848
- Website
- blackdiamondtherapeutics.com
- IPO year
- 2020
- Market cap
- $75.28M
- SEC CIK
- 0001701541
- Latest annual report
- 10-K · Mar 16, 2026
Companies similar to Black Diamond Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRDFCardiff Oncology Inc. | 0.8528 | -4.46% | $66.34M | vs BDTX |
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs BDTX |
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs BDTX |
| NMRANeumora Therapeutics Inc. | 0.3339 | -3.78% | $63.01M | vs BDTX |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs BDTX |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs BDTX |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs BDTX |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs BDTX |